58.39
+6.90%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Vericel
From its filings with the US Securities and Exchange Commission
Vericel is based in Burlington, Massachusetts and is incorporated in Michigan. Its shares trade on Nasdaq under the ticker VCEL. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $276.3m and net income of $16.5m. At that date it held total assets of $488.0m and shareholders' equity of $354.6m. By business, Total MACI implants, kits, and instruments brought in 86.7% of revenue, followed by Epicel at 11.6% and MACI implants, kits, and instruments at 2.1%.
Vericel Corporation is a leading provider of advanced therapies for the sports medicine and severe burn care markets. We have a highly differentiated portfolio of cell therapy and specialty biologic products that combines innovations in biology with medical technologies. We were among the first companies to achieve commercial success in the complex field of cell therapies with treatments that use tissue engineering to regenerate skin and healthy knee cartilage. We currently market two U.S. Food and Drug Administration (“FDA”) approved autologous cell therapy products and one FDA-approved specialty biologic product in the U.S. MACI® is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Since MACI’s commercial launch, the product’s FDA-approved labeling has provided for a treating surgeon to use MACI to treat a patient through an open surgical procedure. In August 2024, the FDA approved a supplemental Biologics License Application (“sBLA”) expanding the MACI indication to add instructions for the arthroscopic delivery of MACI to the product’s approved labeling. MACI Arthro® allows surgeons to evaluate and prepare the cartilage defect site as well as deliver the MACI implant through small incisions using custom-designed arthroscopic instruments developed by the Company (“MACI Arthro instruments”). MACI Arthro became commercially available in the U.S.
Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 4 Feb 1997
- Employees
- 398
- Website
- vcel.com ↗
- Head office
- 25 BLUE SKY DRIVE, BURLINGTON, MA, 01803
- Incorporated in
- MI
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Dr. Robert ZerbeIndependent Chairman of the Board$469,898
- Mr. Dominick ColangeloPresident, Chief Executive Officer, Director, since 2013$10.2m
- Mr. Joseph MaraChief Financial Officer$3.0m
- Mr. Michael HalpinChief Operating Officer$3.3m
- Ms. Karen MahoneyChief Human Resources Officer$3.0m
- Mr. Sean FlynnChief Legal Officer$2.1m
- Dr. Jonathan HopperChief Medical Officer$2.1m
- Ms. Heidi HagenIndependent Director$437,398
- Mr. Kevin MclaughlinIndependent Director$439,898
- Mr. Alan RubinoIndependent Director$447,398
- Dr. Paul WottonIndependent Director$424,898
- Ms. Lisa WrightIndependent Director$424,898
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 35
- Environment
- 10
- Social
- 34
- Governance
- 61
- Women in the workforce
- 38%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Vericel Corp has a number of strengths that give it a competitive advantage in the market. One of its notable strengths is its innovative and high-quality product portfolio. The company offers advanced cell therapies that have shown significant success in treating various medical conditions. This cutting-edge technology attracts customers and positions Vericel as a leader in the industry. Another strength is Vericel's strong research and development capabilities. The company invests heavily in R&D to continuously improve its existing products and develop new ones. This commitment to innovation allows Vericel to stay ahead of its competitors and offer superior treatments to patients. Additionally, Vericel benefits from a robust distribution network. The company has established collaborations with healthcare providers, hospitals, and other organizations worldwide. This extensive network enables Vericel to reach a large customer base and effectively distribute its products. Lastly, Vericel has a talented team of professionals, including experienced researchers and highly skilled employees. This expertise ensures efficient operations and the ability to adapt to changing market dynamics.
Weaknesses
- Despite its strengths, Vericel Corp also faces certain weaknesses. One weakness is its dependence on a limited number of products. While Vericel's existing products are successful, this concentration poses a risk if the market demand for these products declines or if competition intensifies. Another weakness is the regulatory environment surrounding cell therapies. The regulatory requirements for approval and marketing of these therapies can be complex and time-consuming. Vericel needs to navigate this landscape carefully to ensure timely commercialization of its products. Additionally, Vericel's financial performance has been reliant on the success of a few key products. This dependency on a small subset of products introduces financial risk if those products underperform or face challenges in the market. Lastly, Vericel may face challenges in scaling up its manufacturing capabilities to meet increasing demand. The production of cell therapies often requires specialized facilities and processes, which can be costly and resource-intensive.
Opportunities
- Vericel Corp has several opportunities that can contribute to its growth and success. Market expansion is an important opportunity as the demand for innovative cell therapies is expected to increase. Vericel can explore new geographic markets, expand its product offerings, and target additional medical conditions that can benefit from its therapies. Furthermore, partnerships and collaborations can open up new avenues for Vericel. Collaborating with research institutions, healthcare providers, and industry leaders can help accelerate R&D efforts, access new technological advancements, and enhance market presence. Another opportunity lies in leveraging digital technologies and data analytics. Vericel can utilize these tools to optimize its operations, enhance customer experience, and gain valuable insights into patient outcomes. This can lead to improved treatments and increased customer loyalty.
Threats
- Vericel Corp faces certain threats that could impact its performance and market position. One major threat is intense competition in the cell therapy industry. Numerous companies are vying for market share and actively developing similar therapies. Vericel needs to continuously innovate and differentiate its products to stay ahead of the competition. Another threat is the potential for changes in regulations and reimbursement policies. Policy changes can impact market access, pricing, and profitability. Vericel must closely monitor regulatory developments and adapt its strategy accordingly. Additionally, potential disruptions in the supply chain and manufacturing processes could pose threats. Vericel relies on raw materials, resources, and specialized facilities to produce its therapies. Any disruptions in these areas can lead to delays in product availability and impact customer satisfaction. Lastly, Vericel may face risks associated with unexpected adverse events or side effects related to its therapies. Public concerns, legal actions, and damage to the company's reputation can arise if such events occur. Vericel must maintain rigorous safety standards and effectively communicate the benefits and risks of its products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.